Lyssikatos Joseph P's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Dec 21, 2023
- Accession no.
- 0001209191-23-059432
- Filed
- Dec 21, 2023
- Trade date
- Dec 19-20, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $115.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lyssikatos Joseph PCIK 0001967150 | Director, Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 19, 2023 | Common Stock | MOption exerciseAcquired | +200 | $1.12 | +$224 | 200 | Direct | |
| Dec 19, 2023 | Common Stock | SSaleDisposed | −200 | $13.00 | −$2,600 | 0 | Direct | |
| Dec 20, 2023 | Common Stock | MOption exerciseAcquired | +8,688 | $1.12 | +$9,730.56 | 8,688 | Direct | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −8,688 | $13.01F2 | −$113,030.88 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 19, 2023 | Common Stock | MOption exerciseDisposed | −200 | $0.00 | $0 | 323,804 | Direct | |
| Dec 20, 2023 | Common Stock | MOption exerciseDisposed | −8,688 | $0.00 | $0 | 315,116 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $13.00 to $13.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.